James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).
Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).
Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).
Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).
